PortalPublikationenExtracorporeal membrane oxygenation in adult patients with h...

Extracorporeal membrane oxygenation in adult patients with hematologic malignancies and severe acute respiratory failure

Standard

Extracorporeal membrane oxygenation in adult patients with hematologic malignancies and severe acute respiratory failure. / Wohlfarth, Philipp; Ullrich, Roman; Staudinger, Thomas; Bojic, Andja; Robak, Oliver; Hermann, Alexander; Lubsczyk, Barbara; Worel, Nina; Fuhrmann, Valentin; Schoder, Maria; Funovics, Martin; Rabitsch, Werner; Knoebl, Paul; Laczika, Klaus; Locker, Gottfried J; Sperr, Wolfgang R; Schellongowski, Peter.

in: CRIT CARE, Jahrgang 18, Nr. 1, 20.01.2014, S. R20.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Wohlfarth, P, Ullrich, R, Staudinger, T, Bojic, A, Robak, O, Hermann, A, Lubsczyk, B, Worel, N, Fuhrmann, V, Schoder, M, Funovics, M, Rabitsch, W, Knoebl, P, Laczika, K, Locker, GJ, Sperr, WR & Schellongowski, P 2014, 'Extracorporeal membrane oxygenation in adult patients with hematologic malignancies and severe acute respiratory failure', CRIT CARE, Jg. 18, Nr. 1, S. R20. https://doi.org/10.1186/cc13701

APA

Wohlfarth, P., Ullrich, R., Staudinger, T., Bojic, A., Robak, O., Hermann, A., Lubsczyk, B., Worel, N., Fuhrmann, V., Schoder, M., Funovics, M., Rabitsch, W., Knoebl, P., Laczika, K., Locker, G. J., Sperr, W. R., & Schellongowski, P. (2014). Extracorporeal membrane oxygenation in adult patients with hematologic malignancies and severe acute respiratory failure. CRIT CARE, 18(1), R20. https://doi.org/10.1186/cc13701

Vancouver

Wohlfarth P, Ullrich R, Staudinger T, Bojic A, Robak O, Hermann A et al. Extracorporeal membrane oxygenation in adult patients with hematologic malignancies and severe acute respiratory failure. CRIT CARE. 2014 Jan 20;18(1):R20. https://doi.org/10.1186/cc13701

Bibtex

@article{07ec867ed61443e79d0d0ff754d936d6,
title = "Extracorporeal membrane oxygenation in adult patients with hematologic malignancies and severe acute respiratory failure",
abstract = "INTRODUCTION: Acute respiratory failure (ARF) is the main reason for intensive care unit (ICU) admissions in patients with hematologic malignancies (HM). We report the first series of adult patients with ARF and HM treated with extracorporeal membrane oxygenation (ECMO).METHODS: This is a retrospective cohort study on 14 patients with HM (aggressive non-Hodgkin lymphoma (NHL) n = 5; highly aggressive NHL, that is acute lymphoblastic leukemia or Burkitt's lymphoma, n = 5; Hodgkin's lymphoma, n = 2; acute myeloid leukemia, n = 1; multiple myeloma, n = 1) receiving ECMO support due to ARF (all data as medians and interquartile ranges; age: 32 years (22 to 51); simplified acute physiology score II (SAPS II): 51 (42 to 65)). Etiology of ARF was pneumonia (n = 10), thoracic manifestation of NHL (n = 2), sepsis of non-pulmonary origin (n = 1), and transfusion related acute lung injury (n = 1). Diagnosis of HM was established during ECMO in four patients, and five firstly received (immuno-) chemotherapy on ECMO.RESULTS: Prior to ECMO, the PaO2/FiO2-ratio was 60 (53 to 65) and the lung injury score 3.3 (3.3 to 3.7). Three patients received veno-arterial ECMO due acute circulatory failure in addition to ARF, all other patients received veno-venous ECMO. All patients needed vasopressors and five needed hemofiltration. Thrombocytopenia occurred in all patients (lowest platelet count was 20 (11 to 21) G/L). Five major bleeding events were noted. ECMO duration was 8.5 (4 to 16) days. ICU and hospital survival was 50%. All survivors were alive at follow-up (36 (10 to 58) months), five patients were in complete remission, one in partial remission, and one had relapsed.CONCLUSIONS: ECMO therapy is feasible in selected patients with HM and ARF and can be associated with long-term disease-free survival.",
author = "Philipp Wohlfarth and Roman Ullrich and Thomas Staudinger and Andja Bojic and Oliver Robak and Alexander Hermann and Barbara Lubsczyk and Nina Worel and Valentin Fuhrmann and Maria Schoder and Martin Funovics and Werner Rabitsch and Paul Knoebl and Klaus Laczika and Locker, {Gottfried J} and Sperr, {Wolfgang R} and Peter Schellongowski",
year = "2014",
month = jan,
day = "20",
doi = "10.1186/cc13701",
language = "English",
volume = "18",
pages = "R20",
journal = "CRIT CARE",
issn = "1364-8535",
publisher = "Springer Science + Business Media",
number = "1",

}

RIS

TY - JOUR

T1 - Extracorporeal membrane oxygenation in adult patients with hematologic malignancies and severe acute respiratory failure

AU - Wohlfarth, Philipp

AU - Ullrich, Roman

AU - Staudinger, Thomas

AU - Bojic, Andja

AU - Robak, Oliver

AU - Hermann, Alexander

AU - Lubsczyk, Barbara

AU - Worel, Nina

AU - Fuhrmann, Valentin

AU - Schoder, Maria

AU - Funovics, Martin

AU - Rabitsch, Werner

AU - Knoebl, Paul

AU - Laczika, Klaus

AU - Locker, Gottfried J

AU - Sperr, Wolfgang R

AU - Schellongowski, Peter

PY - 2014/1/20

Y1 - 2014/1/20

N2 - INTRODUCTION: Acute respiratory failure (ARF) is the main reason for intensive care unit (ICU) admissions in patients with hematologic malignancies (HM). We report the first series of adult patients with ARF and HM treated with extracorporeal membrane oxygenation (ECMO).METHODS: This is a retrospective cohort study on 14 patients with HM (aggressive non-Hodgkin lymphoma (NHL) n = 5; highly aggressive NHL, that is acute lymphoblastic leukemia or Burkitt's lymphoma, n = 5; Hodgkin's lymphoma, n = 2; acute myeloid leukemia, n = 1; multiple myeloma, n = 1) receiving ECMO support due to ARF (all data as medians and interquartile ranges; age: 32 years (22 to 51); simplified acute physiology score II (SAPS II): 51 (42 to 65)). Etiology of ARF was pneumonia (n = 10), thoracic manifestation of NHL (n = 2), sepsis of non-pulmonary origin (n = 1), and transfusion related acute lung injury (n = 1). Diagnosis of HM was established during ECMO in four patients, and five firstly received (immuno-) chemotherapy on ECMO.RESULTS: Prior to ECMO, the PaO2/FiO2-ratio was 60 (53 to 65) and the lung injury score 3.3 (3.3 to 3.7). Three patients received veno-arterial ECMO due acute circulatory failure in addition to ARF, all other patients received veno-venous ECMO. All patients needed vasopressors and five needed hemofiltration. Thrombocytopenia occurred in all patients (lowest platelet count was 20 (11 to 21) G/L). Five major bleeding events were noted. ECMO duration was 8.5 (4 to 16) days. ICU and hospital survival was 50%. All survivors were alive at follow-up (36 (10 to 58) months), five patients were in complete remission, one in partial remission, and one had relapsed.CONCLUSIONS: ECMO therapy is feasible in selected patients with HM and ARF and can be associated with long-term disease-free survival.

AB - INTRODUCTION: Acute respiratory failure (ARF) is the main reason for intensive care unit (ICU) admissions in patients with hematologic malignancies (HM). We report the first series of adult patients with ARF and HM treated with extracorporeal membrane oxygenation (ECMO).METHODS: This is a retrospective cohort study on 14 patients with HM (aggressive non-Hodgkin lymphoma (NHL) n = 5; highly aggressive NHL, that is acute lymphoblastic leukemia or Burkitt's lymphoma, n = 5; Hodgkin's lymphoma, n = 2; acute myeloid leukemia, n = 1; multiple myeloma, n = 1) receiving ECMO support due to ARF (all data as medians and interquartile ranges; age: 32 years (22 to 51); simplified acute physiology score II (SAPS II): 51 (42 to 65)). Etiology of ARF was pneumonia (n = 10), thoracic manifestation of NHL (n = 2), sepsis of non-pulmonary origin (n = 1), and transfusion related acute lung injury (n = 1). Diagnosis of HM was established during ECMO in four patients, and five firstly received (immuno-) chemotherapy on ECMO.RESULTS: Prior to ECMO, the PaO2/FiO2-ratio was 60 (53 to 65) and the lung injury score 3.3 (3.3 to 3.7). Three patients received veno-arterial ECMO due acute circulatory failure in addition to ARF, all other patients received veno-venous ECMO. All patients needed vasopressors and five needed hemofiltration. Thrombocytopenia occurred in all patients (lowest platelet count was 20 (11 to 21) G/L). Five major bleeding events were noted. ECMO duration was 8.5 (4 to 16) days. ICU and hospital survival was 50%. All survivors were alive at follow-up (36 (10 to 58) months), five patients were in complete remission, one in partial remission, and one had relapsed.CONCLUSIONS: ECMO therapy is feasible in selected patients with HM and ARF and can be associated with long-term disease-free survival.

U2 - 10.1186/cc13701

DO - 10.1186/cc13701

M3 - SCORING: Journal article

C2 - 24443905

VL - 18

SP - R20

JO - CRIT CARE

JF - CRIT CARE

SN - 1364-8535

IS - 1

ER -